Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
A randomized phase 2 clinical trial has recently shown no benefit of the combination eribulin and pembrolizumab over pembrolizumab alone in HR + metastatic breast cancer patients (NCT03051659). Here, the authors are reporting the final OS data and biomarker analyses on a subset of samples to analyze...
Main Authors: | Tanya E. Keenan, Jennifer L. Guerriero, Romualdo Barroso-Sousa, Tianyu Li, Tess O’Meara, Anita Giobbie-Hurder, Nabihah Tayob, Jiani Hu, Mariano Severgnini, Judith Agudo, Ines Vaz-Luis, Leilani Anderson, Victoria Attaya, Jihye Park, Jake Conway, Meng Xiao He, Brendan Reardon, Erin Shannon, Gerburg Wulf, Laura M. Spring, Rinath Jeselsohn, Ian Krop, Nancy U. Lin, Ann Partridge, Eric P. Winer, Elizabeth A. Mittendorf, David Liu, Eliezer M. Van Allen, Sara M. Tolaney |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-09-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-021-25769-z |
Similar Items
-
How drug resistance takes shape
by: Rinath Jeselsohn, et al.
Published: (2016-03-01) -
Eribulin drug review
by: Nishitha Shetty, et al.
Published: (2014-01-01) -
Eribulin in Cancer Treatment
by: Umang Swami, et al.
Published: (2015-08-01) -
Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01) -
Eribulin mesylate in the treatment of metastatic breast cancer
by: Jain S, et al.
Published: (2012-01-01)